Composition for preventing or treating pulmonary fibrosis disease
AssigneeFnct Biotech, Inc.
InventorsSu Jae LEE, In Yeong YUN, Jae Hyeok KANG
Life of this patent
Estimating the term…
Abstract
A novel use of granulocyte colony-stimulating factor, also known as colony-stimulating factor 3 (CSF3) is disclosed. An anticancer adjuvant containing an inhibitor of CSF3 is disclosed. Uses of CSF3 as a biomarker or therapeutic target for pulmonary fibrosis are disclosed. In addition, A pharmaceutical composition for treating pulmonary fibrosis containing an inhibitor of CSF3 and a treatment method of pulmonary fibrosis are disclosed.
Claims32
A composition for combined anticancer therapy, comprising a Granulocyte-colony stimulating factor 3 (CSF3) inhibitor as an active ingredient.
A pharmaceutical composition for preventing or treating a pulmonary fibrosis disease, comprising a Granulocyte-colony stimulating factor 3 (CSF3) inhibitor as an active ingredient.
Dependencies are inferred from the claim text.